Texas has run out of sotrovimab, a key monoclonal antibody treatment against omicron, due to a national shortage.

The Texas Department of Health and Human Services said the federal government controls the distribution of the monoclonal antibodies and that it expects a new shipment in January.

"Other monoclonal antibodies have not shown to be effective against the Omicron variant, which now accounts for more than 90 percent of new cases," the department said.

The department said its infusion centers will continue to offer antibodies that are helpful for other variants of COVID-19. It also said it will soon make newly approved antiviral drugs from the Food and Drug Administration available to the public.

FAUCI FINALLY ADMITS OMICRON IS LESS SEVERE

The U.S. Department of Health and Human Services announced it distributed 2,694 doses of sotrovimab to Texas earlier in December. It advised that supply was very limited and said the treatment should be reserved for the "highest risk outpatients."

The main distribution centers of monoclonal antibodies in the state are located in Austin, El Paso, Fort Worth, San Antonio, and The Woodlands, a press release from the Texas Health and Human Services Department said.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

Texas recently reached a record high of new COVID-19 cases on Monday, according to data from Johns Hopkins University. It had 53,656 infections and 163 new deaths. Notably, the single-day death count is below the record high of 1,183 it reached on Oct. 13, 2021.

Texas health officials advised vaccination against COVID-19 in order to prevent serious infections. Texas has 71.33% of its population ages 5 and older vaccinated with at least one dose of the vaccine, according to data from the state. This is below the national average of 77.6%, according to data from the Centers for Disease Control and Prevention.